首页> 外文期刊>Journal of Cancer Research and Clinical Oncology >Effects of paclitaxel in combination with radiation on human head and neck cancer cells (ZMK-1), cervical squamous cell carcinoma (CaSki), and breast adenocarcinoma cells (MCF-7).
【24h】

Effects of paclitaxel in combination with radiation on human head and neck cancer cells (ZMK-1), cervical squamous cell carcinoma (CaSki), and breast adenocarcinoma cells (MCF-7).

机译:紫杉醇联合放疗对人头颈部癌细胞(ZMK-1),宫颈鳞状细胞癌(CaSki)和乳腺腺癌细胞(MCF-7)的影响。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND AND PURPOSE: The anticancer drug paclitaxel, a natural product from Taxus brevifolia, is a microtubule-stabilising agent, which has been shown to block different cells in the G2/M phase of the cell cycle and so modulate their radioresponsiveness. We investigated the radiosensitizing potential of paclitaxel in human head and neck cancer cells (ZMK-1), in cervical squamous cell carcinoma cells (CaSki) and in breast adenocarcinoma cells (MCF-7). METHODS: ZMK-1 cells were incubated with paclitaxel for 3, 9, or 24 h before irradiation. ZMK-1-, CaSki- and MCF-7 cells were incubated with paclitaxel for 24 h after irradiation. The paclitaxel concentration (70 nM, 7 nM, 0.7 nM) was chosen to obtain equivalent toxicity at the different incubation times (3 h, 9 h, 24 h respectively). Radiation doses were from 0 to 8 Gy. Cell survival was measured by a standard clonogenic assay after a 9-day incubation. Flow cytometry was used to measure the capacity of paclitaxel to cause accumulation of cells in the G2/M phase of the cell cycle. RESULTS: Paclitaxel alone was cytotoxic in a time- and concentration-dependent manner. Up to 36% of the ZMK-1 cells accumulated in G2/M after treatment for 24-36 h. If the cells were incubated with paclitaxel before irradiation the isoeffect enhancement ratios for ZMK-1 cells, determined at the 37% survival level, were 0.81, 1.48 and 1.15 for 3-h, 9-h, and 24-h pre-incubations respectively. For a paclitaxel incubation of 24 h after irradiation, the isoeffect enhancement ratios, determined at the 37% survival level, were 0.72, 0.76 and 1.2 for the ZMK-1. CaSki, and MCF-7 cells respectively. CONCLUSION: In the three cell lines no radiosensitizing effect of paclitaxel could be demonstrated unambiguously. The use of asynchronized cells or the support of cellular repair mechanisms while the cells are blocked in G2/M could partly explain the results.
机译:背景和目的:抗癌药紫杉醇是短叶红豆杉的天然产物,是一种微管稳定剂,已显示在细胞周期的G2 / M期阻断不同的细胞,从而调节其放射反应性。我们研究了紫杉醇在人头和颈部癌细胞(ZMK-1),宫颈鳞状细胞癌细胞(CaSki)和乳腺腺癌细胞(MCF-7)中的放射增敏潜力。方法:将ZMK-1细胞与紫杉醇一起孵育3、9或24小时,然后照射。辐射后,ZMK-1-,CaSki-和MCF-7细胞与紫杉醇孵育24小时。选择紫杉醇浓度(70 nM,7 nM,0.7 nM)以在不同的孵育时间(分别为3 h,9 h,24 h)获得同等毒性。辐射剂量为0至8 Gy。培养9天后,通过标准克隆形成测定法测量细胞存活。流式细胞仪用于测量紫杉醇在细胞周期的G2 / M期引起细胞蓄积的能力。结果:单独的紫杉醇具有时间和浓度依赖性的细胞毒性。处理24-36小时后,高达36%的ZMK-1细胞积聚在G2 / M中。如果在辐照前将细胞与紫杉醇一起孵育,则在37%的存活水平下测定的ZMK-1细胞的3小时,9小时和24小时预培养的同工效应增强比分别为0.81、1.48和1.15。 。对于辐射后24 h的紫杉醇温育,在37%生存水平下确定的ZMK-1的等效效应增强比为0.72、0.76和1.2。 CaSki和MCF-7细胞分别。结论:在这三种细胞系中,不能明确显示紫杉醇的放射增敏作用。当细胞在G2 / M中受阻时,使用异步细胞或细胞修复机制的支持可以部分解释结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号